Expression of NF45 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10149-10157

  Huang, Qingfeng ^a   He, Xiaojuan ^a   Qiu, Xiaojun ^a   Liu, Xianchen ^a   Sun, Guan ^a   Guo, Jun ^a   Ding, Zongmei ^a   Yang, Lixiang ^b   Ban, Na ^a   Tao, Tao ^a   Wang, Dongling ^a  

^a NANTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Glioma; Human; NF45; Proliferation

Indexed keywords

CYCLIN E; CYCLINE; INTERLEUKIN ENHANCER BINDING FACTOR 2; KI 67 ANTIGEN; SMALL INTERFERING RNA; ILF2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING; AGED; BRAIN TUMOR; DISEASE COURSE; GENETIC TRANSFECTION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE;

ADULT; AGED; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR FACTOR 45 PROTEIN; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84921486778     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2310-5     Document Type: Article

References (27)

1. Kleihues P et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215–25. discussion 226-9.
2. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol. 2004;16(6):607–13.
3. Venkataramanaa NK et al. Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas. Asian J Neurosurg. 2013;8(1):9–14.
4. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93–108.
5. Mrugala MM. Advances and challenges in the treatment of glioblas-toma: a clinician’s perspective. Discov Med. 2013;15(83):221–30.
6. Kao PN et al. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. J Biol Chem. 1994;269(32):20691–9.
7. Saunders LR et al. Characterization of two evolutionarily conserved, alternatively spliced nuclear phosphoproteins, NFAR-1 and -2, that function in mRNA processing and interact with the double-stranded RNA-dependent protein kinase, PKR. J Biol Chem. 2001;276(34): 32300–12.
8. Scherl A et al. Functional proteomic analysis of human nucleolus. Mol Biol Cell. 2002;13(11):4100–9.
9. Zhou Z et al. Comprehensive proteomic analysis of the human spliceosome. Nature. 2002;419(6903):182–5.
10. Zhao G et al. NF45/ILF2 tissue expression, promoter analysis, and interleukin-2 transactivating function. Exp Cell Res. 2005;305(2): 312–23.
11. Lopez-Fernandez LA, Parraga M, del Mazo J. Ilf2 is regulated during meiosis and associated to transcriptionally active chromatin. Mech Dev. 2002;111(1–2):153–7.
12. Faye MD et al. Nucleotide composition of cellular internal ribosome entry sites defines dependence on NF45 and predicts a posttranscrip-tional mitotic regulon. Mol Cell Biol. 2013;33(2):307–18.
13. Graber TE et al. NF45 functions as an IRES trans-acting factor that is required for translation of cIAP1 during the unfolded protein response. Cell Death Differ. 2010;17(4):719–29.
14. Shim C et al. Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res. 1998;4(12):3045–50.
15. Shamanna RA et al. Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene. 2013;32(43): 5176–85.
16. Hang Q et al. Expression of Spy1 protein in human non-Hodgkin’s lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. Med Oncol. 2012;29(5):3504–14.
17. Yamashita Y et al. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. J Neurooncol. 2010;100(1):43–9.
18. Chen J et al. Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene. 1996;13(7):1395–403.
19. Jung JM et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995;11(10):2021–8.
20. Kokunai T, Izawa I, Tamaki N. Over expression of p21WAF1/CIP1 induces cell differentiation and growth inhibition in a human glioma cell line. Int J Cancer. 1998;75(4):643–8.
21. Korkolopoulou P et al. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol. 1998;95(6):617–24.
22. Tamiya T et al. High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol. 2001;101(4):334–40.
23. Tanikawa M et al. Potent prostaglandin A1 analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E. J Biol Chem. 1998;273(29):18522–7.
24. Wang JA et al. Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53. Int J Radiat Biol. 1999;75(3):301–16.
25. Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264(23):13856–64.
26. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88(12):2887.
27. Sakamoto S et al. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol. 2009;29(13):3754–69.